STING1 and neoplasm: This system demonstrated synergistic sono‐immunotherapeutic effects in organoid and mouse tumor models.[124a] To combat hypoxia, a critical limitation of SDT that impairs ROS generation, Zhang and colleagues developed a liposomal PFH nanodroplet encapsulating the STING agonist DMXAA and the sonosensitizer IR‐780, referred to as IDP.[124b] By loading O2 gas into the PFH core, the O2‐filled nanodroplet (IDP@O2) was engineered to respond to ultrasound irradiation.